Beyond the Deal: Recursion’s Transformational Partnership with Roche and Genentech
September 23, 2022 at 05:55 pm EDT
Share
Beyond the Deal: Recursion's Transformational Partnership with Roche and Genentech
September 23, 2022
Written By:
No items found.
Read the post ›
In December 2021, we entered into a multi-year, strategic collaboration with Roche and Genentech in key areas of neuroscience and an oncology indication. Through the partnership, we are working with both Roche and Genentech's R&D units to leverage the Recursion OS and Maps of Biology, along with extensive single-cell perturbation screening data from Roche and Genentech, to rapidly identify novel biological relationships to initiate and advance therapeutic programs.
For a behind-the-scenes look at the structure and progress of this expansive partnership, watch the video below and read more on Genentech's "Beyond the Deal" blog series.
Attachments
Original Link
Original Document
Permalink
Disclaimer
Recursion Pharmaceuticals Inc. published this content on 23 September 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 23 September 2022 21:54:00 UTC.
Recursion Pharmaceuticals, Inc. is a clinical-stage TechBio company decoding biology to industrialize drug discovery. Its Recursion Operating System (OS), a platform built across diverse technologies, enables the Company to map and navigate trillions of biological and chemical relationships within the Recursion Data Universe. The Company integrates physical and digital components as iterative loops of atoms and bits scaling wet lab biology and chemistry data organized into virtuous cycles with computational tools to rapidly translate in silico hypotheses into validated insights and novel chemistry. Its clinical programs include REC-994, REC-2282, REC-4881 and REC-3964. REC-994 is an orally bioavailable, superoxide scavenger small molecule being development for the treatment of symptomatic cerebral cavernous malformation (CCM). REC-2282 for the potential treatment of neurofibromatosis type 2. REC-3964 for the prevention of recurrent Clostridioides difficile infection.
RECURSION PHARMACEUTICALS, INC. 
